Ruxolitinib-induced reactivation of cytomegalovirus and Epstein-Barr virus in graft-versus-host disease. Lebon D, Dujardin A, Caulier A, Joris M, et al. Leuk Res 2022;125:107005.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Lebon D, Dujardin A, Caulier A, Joris M, et al. Ruxolitinib-induced reactivation of cytomegalovirus and Epstein-Barr virus in graft-versus-host disease. Leuk Res 2022;125:107005.
PMID: 36580876